Annual report
2934.TEDINET S100YYK8
Period2025-06-01 → 2026-05-31
Filed2026-08-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 141
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥22.2bn | 2025-06-01 → 2026-05-31 | Cons. | Net sales |
| Revenue | ¥21.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales |
| Revenue | ¥17.7bn | 2023-06-01 → 2024-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥16.8bn | 2022-06-01 → 2023-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.9bn | 2021-06-01 → 2022-05-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥312m | 2025-06-01 → 2026-05-31 | Cons. | Operating income |
| Operating income | ¥294m | 2024-06-01 → 2025-05-31 | Cons. | Operating income |
| Ordinary income | ¥415m | 2025-06-01 → 2026-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥232m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income |
| Ordinary income | −¥695m | 2023-06-01 → 2024-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.8bn | 2022-06-01 → 2023-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥712m | 2021-06-01 → 2022-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥101m | 2025-06-01 → 2026-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥248m | 2024-06-01 → 2025-05-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥321m | 2025-06-01 → 2026-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥88m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.1bn | 2023-06-01 → 2024-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.9bn | 2022-06-01 → 2023-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥401m | 2021-06-01 → 2022-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥276m | 2025-06-01 → 2026-05-31 | Cons. | Profit loss |
| Net income | ¥132m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss |
| Total assets | ¥9.6bn | at 2026-05-31 | Cons. | Assets |
| Total assets | ¥9.2bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥11.4bn | at 2024-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥7.2bn | at 2023-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥6.1bn | at 2022-05-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.1bn | at 2026-05-31 | Cons. | Liabilities |
| Total liabilities | ¥7.2bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.5bn | at 2026-05-31 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥1.9bn | at 2024-05-31v | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-05-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.2bn | at 2022-05-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2026-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.1bn | at 2026-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-05-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.0bn | at 2022-05-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥454m | 2025-06-01 → 2026-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥509m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2023-06-01 → 2024-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.8bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥367m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.2bn | 2025-06-01 → 2026-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥471m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2023-06-01 → 2024-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥860m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥758m | 2025-06-01 → 2026-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥623m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.4bn | 2023-06-01 → 2024-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.6bn | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-60.64 | 2025-06-01 → 2026-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.42 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-429.05 | 2023-06-01 → 2024-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-410.6 | 2022-06-01 → 2023-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.64 | 2021-06-01 → 2022-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥17.21 | 2024-06-01 → 2025-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥86.68 | 2021-06-01 → 2022-05-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥229.99 | at 2026-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥269.11 | at 2025-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥229.59 | at 2024-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥525.78 | at 2023-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥907.43 | at 2022-05-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 12.8% | at 2026-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 15.3% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 10.0% | at 2024-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2023-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2022-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.9% | 2024-06-01 → 2025-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.7% | 2021-06-01 → 2022-05-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 201 | at 2026-05-31 | Cons. | Number of employees |
| Employees | 202 | at 2025-05-31 | Cons. | Number of employees |
| Employees | 315 | at 2024-05-31v | Cons. | Number of employees |
| Employees | 255 | at 2023-05-31v | Cons. | Number of employees |
| Employees | 278 | at 2022-05-31v | Cons. | Number of employees |
| Revenue | ¥6.1bn | 2025-06-01 → 2026-05-31 | Standalone | Net sales |
| Revenue | ¥6.6bn | 2024-06-01 → 2025-05-31 | Standalone | Net sales |
| Revenue | ¥8.1bn | 2023-06-01 → 2024-05-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥9.4bn | 2022-06-01 → 2023-05-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥9.3bn | 2021-06-01 → 2022-05-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥121m | 2025-06-01 → 2026-05-31 | Standalone | Operating income |
| Operating income | ¥263m | 2024-06-01 → 2025-05-31 | Standalone | Operating income |
| Ordinary income | ¥85m | 2025-06-01 → 2026-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥199m | 2024-06-01 → 2025-05-31 | Standalone | Ordinary income |
| Ordinary income | −¥219m | 2023-06-01 → 2024-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.7bn | 2022-06-01 → 2023-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥724m | 2021-06-01 → 2022-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥651m | 2025-06-01 → 2026-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥95m | 2024-06-01 → 2025-05-31 | Standalone | Income before income taxes |
| Net income | −¥639m | 2025-06-01 → 2026-05-31 | Standalone | Profit loss |
| Net income | ¥48m | 2024-06-01 → 2025-05-31 | Standalone | Profit loss |
| Net income | −¥2.1bn | 2023-06-01 → 2024-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.7bn | 2022-06-01 → 2023-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥450m | 2021-06-01 → 2022-05-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥7.5bn | at 2026-05-31 | Standalone | Assets |
| Total assets | ¥6.5bn | at 2025-05-31 | Standalone | Assets |
| Total assets | ¥7.9bn | at 2024-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.8bn | at 2023-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.3bn | at 2022-05-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥6.0bn | at 2026-05-31 | Standalone | Liabilities |
| Total liabilities | ¥4.6bn | at 2025-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.5bn | at 2026-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2025-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.4bn | at 2024-05-31v | Standalone | Net assets |
| Net assets / equity | ¥2.8bn | at 2023-05-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.2bn | at 2022-05-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥833m | at 2026-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2025-05-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-120.5 | 2025-06-01 → 2026-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.54 | 2024-06-01 → 2025-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-438.4 | 2023-06-01 → 2024-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-357.08 | 2022-06-01 → 2023-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.91 | 2021-06-01 → 2022-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥9.43 | 2024-06-01 → 2025-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥97.45 | 2021-06-01 → 2022-05-31v | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥281.82 | at 2026-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥371.65 | at 2025-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥280.35 | at 2024-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥589.16 | at 2023-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥918.35 | at 2022-05-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 20.1% | at 2026-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.8% | at 2025-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.6% | at 2024-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.4% | at 2023-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.0% | at 2022-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.9% | 2024-06-01 → 2025-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.5% | 2021-06-01 → 2022-05-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 5,336,369 | at 2026-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,220,195 | at 2025-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,137,046 | at 2024-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,892,098 | at 2023-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,757,616 | at 2022-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 67 | at 2026-05-31 | Standalone | Number of employees |
| Employees | 64 | at 2025-05-31 | Standalone | Number of employees |
| Employees | 63 | at 2024-05-31v | Standalone | Number of employees |
| Employees | 49 | at 2023-05-31v | Standalone | Number of employees |
| Employees | 54 | at 2022-05-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 74
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-06-01 → 2026-05-31 | ¥365,000 |
| Reconciling Itemsreconciling | depreciation | 2025-06-01 → 2026-05-31 | ¥317,000 |
| Reconciling Itemsreconciling | revenue | 2025-06-01 → 2026-05-31 | −¥142m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-06-01 → 2026-05-31 | −¥142m |
| Reconciling Itemsreconciling | segment assets | at 2026-05-31 | ¥986m |
| Reconciling Itemsreconciling | segment profit | 2025-06-01 → 2026-05-31 | −¥364m |
| Healthcare Marketing Businessreportable segment | capex | 2025-06-01 → 2026-05-31 | ¥867m |
| Healthcare Marketing Businessreportable segment | depreciation | 2025-06-01 → 2026-05-31 | ¥13m |
| Healthcare Marketing Businessreportable segment | employees | at 2026-05-31 | 67 pure |
| Healthcare Marketing Businessreportable segment | revenue | 2025-06-01 → 2026-05-31 | ¥11.7bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2025-06-01 → 2026-05-31 | ¥11.6bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2025-06-01 → 2026-05-31 | ¥117m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2026-05-31 | ¥2.6bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2025-06-01 → 2026-05-31 | ¥237m |
| Healthcare Sales Businessreportable segment | capex | 2025-06-01 → 2026-05-31 | ¥2m |
| Healthcare Sales Businessreportable segment | depreciation | 2025-06-01 → 2026-05-31 | ¥6m |
| Healthcare Sales Businessreportable segment | employees | at 2026-05-31 | 78 pure |
| Healthcare Sales Businessreportable segment | revenue | 2025-06-01 → 2026-05-31 | ¥5.4bn |
| Healthcare Sales Businessreportable segment | revenue external | 2025-06-01 → 2026-05-31 | ¥5.4bn |
| Healthcare Sales Businessreportable segment | revenue intersegment | 2025-06-01 → 2026-05-31 | ¥20m |
| Healthcare Sales Businessreportable segment | segment assets | at 2026-05-31 | ¥4.5bn |
| Healthcare Sales Businessreportable segment | segment profit | 2025-06-01 → 2026-05-31 | −¥45m |
| Medical Care Sales Businessreportable segment | capex | 2025-06-01 → 2026-05-31 | ¥51m |
| Medical Care Sales Businessreportable segment | depreciation | 2025-06-01 → 2026-05-31 | ¥18m |
| Medical Care Sales Businessreportable segment | employees | at 2026-05-31 | 42 pure |
| Medical Care Sales Businessreportable segment | revenue | 2025-06-01 → 2026-05-31 | ¥5.3bn |
| Medical Care Sales Businessreportable segment | revenue external | 2025-06-01 → 2026-05-31 | ¥5.3bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2025-06-01 → 2026-05-31 | ¥4m |
| Medical Care Sales Businessreportable segment | segment assets | at 2026-05-31 | ¥1.6bn |
| Medical Care Sales Businessreportable segment | segment profit | 2025-06-01 → 2026-05-31 | ¥484m |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-06-01 → 2026-05-31 | ¥920m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-06-01 → 2026-05-31 | ¥37m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-06-01 → 2026-05-31 | ¥22.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-06-01 → 2026-05-31 | ¥22.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-06-01 → 2026-05-31 | ¥142m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-05-31 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-06-01 → 2026-05-31 | ¥676m |
| Reconciling Itemsreconciling | capex | 2024-06-01 → 2025-05-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2024-06-01 → 2025-05-31 | ¥367,000 |
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2025-05-31 | −¥141m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2025-05-31 | −¥141m |
| Reconciling Itemsreconciling | segment assets | at 2025-05-31 | ¥1.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2025-05-31 | −¥383m |
| Healthcare Marketing Businessreportable segment | capex | 2024-06-01 → 2025-05-31 | ¥7m |
| Healthcare Marketing Businessreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥12m |
| Healthcare Marketing Businessreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥9.8bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥9.7bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥120m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2025-05-31 | ¥1.4bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥127m |
| Healthcare Sales Businessreportable segment | capex | 2024-06-01 → 2025-05-31 | ¥11m |
| Healthcare Sales Businessreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥5m |
| Healthcare Sales Businessreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥6.1bn |
| Healthcare Sales Businessreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥6.1bn |
| Healthcare Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥17m |
| Healthcare Sales Businessreportable segment | segment assets | at 2025-05-31 | ¥5.6bn |
| Healthcare Sales Businessreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥42m |
| Medical Care Sales Businessreportable segment | capex | 2024-06-01 → 2025-05-31 | ¥36m |
| Medical Care Sales Businessreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥14m |
| Medical Care Sales Businessreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥5.7bn |
| Medical Care Sales Businessreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥5.7bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥4m |
| Medical Care Sales Businessreportable segment | segment assets | at 2025-05-31 | ¥467m |
| Medical Care Sales Businessreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥508m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-06-01 → 2025-05-31 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-06-01 → 2025-05-31 | ¥31m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2025-05-31 | ¥21.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2025-05-31 | ¥21.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥141m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-05-31 | ¥7.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2025-05-31 | ¥677m |
| Healthcare Marketing Businessreportable segment | employees | at 2026-05-31 | 9 pure |
| Healthcare Sales Businessreportable segment | employees | at 2026-05-31 | 28 pure |
| Medical Care Sales Businessreportable segment | employees | at 2026-05-31 | 16 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,619
| Item | Context | Value | Unit |
|---|---|---|---|
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.1022 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0006 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.6196 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 2369000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.4439 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 1000000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.1874 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 253300 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0475 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 160100 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0300 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 153135 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0287 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 86500 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0162 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 73400 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0138 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 59000 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0111 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 53135 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0100 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 49000 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0092 | |
| Number of shares held | CurrentYearInstant | 4256570 | |
| Shareholding ratio | CurrentYearInstant | 0.7977 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 100 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 5333100 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 53331 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 3169 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 5336369 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 53331 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 100 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 100 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | － | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | － | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | － | |
| Number of male directors and other officers | FilingDateInstant | 9 | |
| Number of female directors and other officers | FilingDateInstant | － | |
| Ratio of female directors and other officers | FilingDateInstant | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000NakamuraAtsuhiroMember | 3369000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000HiguchiYuyaMember | 800 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000HasumiTomotakeMember | 101000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000IamuraAkitoshiMember | 3200 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |